Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.
暂无分享,去创建一个
W. Sellers | M. P. Dillon | Y. Mishina | Mallika Singh | E. Lees | W. Shao | S. Ramurthy | S. Subramanian | L. Setti | B. Appleton | Jacob R. Haling | P. Amiri | D. Stuart | V. Sethuraman | Shenlin Huang | Mohammad Hekmat-Nejad | A. Q. Hassan | M. Burger | Anne van Abbema | Huw R. Tanner | Jing Yuan | Richard Zang | Laura Tandeske | John E. Tellew | Lesley A Mathews Griner | R. Aversa | P. Barsanti | Cheng-Hai Hu | Qin Yue | Aaron Smith | A. Chaudhary | M. Mamo | Yingyun Wang | Yan Lou | G. Nishiguchi | Hanne Merritt | Alice C Rico | V. Polyakov | H. Tian | B. Taft | L. L. La Bonte | S. Vaziri | Kalyani Gampa | Fei Feng | V. Cooke | V. Tamez | R. Iyer | Lifeng Wan | Laura R. La Bonte | William R. Sellers | Jacob Haling | Benjamin R. Taft | Gisele A. Nishiguchi | Brent A. Appleton | A. Quamrul Hassan | Lesley A. Mathews Griner | Michael P. Dillon